An observational study in Resistance Bacterial and Enterobacteriaceae Infections, sponsored by Centre Hospitalier Universitaire de Besancon. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2022-03-10.
Sponsored by Centre Hospitalier Universitaire de Besancon · Observational
Among 12 studies in Enterobacteriaceae Infections with a site in France — 3 open to participants now, 3 under way, 1 of them phase 3. Enterobacteriaceae Infections · France.
Among the 12 studies in Enterobacteriaceae Infections with a site in France, this one is one of 2 that started in 2017, is one of 9 observational ones, and was the 4th registered.
59 studies on the registry are indexed under Enterobacteriaceae Infections; 14 are open to participants now.
Browse Enterobacteriaceae Infections studies →3 of the 12 studies in Enterobacteriaceae Infections with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–105
Centre Hospitalier Universitaire de Nīmes · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 9 Enterobacteriaceae Infections studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is below the median of 300 across 30 observational studies indexed under Enterobacteriaceae Infections.
Median enrollment 19 across the 3 interventional studies, 163 across the 9 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Besancon is the lead sponsor of 450 studies on the registry; 97 are open to participants now.
Centre Hospitalier Universitaire de Besancon has 1 study filed under Enterobacteriaceae Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Enterobacteriaceae Infections with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07345923University Hospital, Strasbourg, FrancePredictive Value of a Rectal Swab With Detection of Enterobacteria (ESBL-E), Carbapenemases, and High-level Cephalosporinase (HLC) on the Risk of Infections With C3G-resistant Enterobacteria | 2027-04 |
| NCT07676513Centre Hospitalier Universitaire de NīmesGenomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Enterobacteriaceae Infections with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The continuing spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) is among the most important problems in antimicrobial resistance. It is also a good model to investigate the epidemiological complexity of resistance in Enterobacteriaceae. Available data on the transmission determinants of ESBL-PE in community settings are scarce, methodologically limited and mostly based on single centre studies. A comprehensive investigation using present typing and modelling techniques is warranted to develop a sound quantitative understanding of the interactions involved. A consortium of investigators with diverse expertise from countries with high and low endemicity of ESBL-EP has been created. Transmission and persistence of ESBL-PE within households and long-term care facilities will be studied. Individual and group-level determinants for transmission and persistence will be quantified, together with other ecological variables including environmental, food and wastewater contamination. Advanced molecular typing techniques and state of the art analytical methods will be used. Data generated in this project will directly inform a suite of mathematical models which, in addition to encapsulating current understanding of the processes, will be used to explore the potential effectiveness of different interventions to control ESBL-PE spread. The expected outputs are a comprehensive characterisation of ESBL-PE transmission considering bacterial clones and mobile genetic elements, as well as individual and ecologic-level factors in different settings, to inform public health authorities about interventions that should be prioritised to control transmission of these organisms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
Biological: ESBL-producing enterobacteriaceae carriage
Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
Biological: ESBL-producing enterobacteriaceae carriage
Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
Transmission of ESBL-producing E. coli and K. pneumoniae (ESBL-E) in the community (LTCF residents and in households)
We will assess * For the cohort 'LTCF': the number of LTCF residents contaminated with an ESBL-E from other residents or from the environment within 35 weeks. * For the cohort 'Household': the number of people (sharing household with a ESBL-E carrying patient which has been discharged from the hospital) contaminated with ESBL-E within 4 months. These two measurements will be aggregated to arrive at one reported value : the number of secondary cases from one index case (ratio).
Time frame: For the cohort 'LTCF': 35 weeks ; For the cohort 'Household': 4 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2017 to primary completion in Jul 2019, 28 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Enterobacteriaceae Infections →
Centre Hospitalier Universitaire de Besancon →